aurobindo pharma
Jump to
2031 Results Found
  • Aurobindo Pharma gets USFDA nod for generic Droxidopa capsules Feb 19, 2021 12:32 PM IST

    Aurobindo Pharma gets USFDA nod for generic Droxidopa capsules

    The approved product is a generic version of Lundbeck NA Ltd's Northera capsules.

  • Weekly Tactical Pick | Aurobindo Pharma Feb 19, 2021 10:44 AM IST

    Weekly Tactical Pick | Aurobindo Pharma

    Valuation at a discount to peers, but significant scope for margin improvement

  • Buy Aurobindo Pharma; target of Rs 1100: Sharekhan Feb 16, 2021 05:24 PM IST

    Buy Aurobindo Pharma; target of Rs 1100: Sharekhan

    Sharekhan is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1100 in its research report dated February 11, 2021.

  • Buy Aurobindo Pharma; target of Rs 1165: ICICI Direct Feb 15, 2021 06:59 PM IST

    Buy Aurobindo Pharma; target of Rs 1165: ICICI Direct

    ICICI Direct is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1165 in its research report dated February 11, 2021.

  • Aurobindo Pharma: Vaccine and API plans inject add-on growth levers Feb 12, 2021 11:06 AM IST

    Aurobindo Pharma: Vaccine and API plans inject add-on growth levers

    In the injectables space, Aurobindo Pharma remains constructive and targets to almost double from current annual sales base of $380 million to $650-700 million in three years backed by new plants in the US and Vizag

  • Aurobindo Pharm Standalone December 2020 Net Sales at Rs 3,710.86 crore, up 10.92% Y-o-Y Feb 11, 2021 10:44 AM IST

    Aurobindo Pharm Standalone December 2020 Net Sales at Rs 3,710.86 crore, up 10.92% Y-o-Y

  • Aurobindo Pharm Consolidated December 2020 Net Sales at Rs 6,364.91 crore, up 7.97% Y-o-Y Feb 11, 2021 10:44 AM IST

    Aurobindo Pharm Consolidated December 2020 Net Sales at Rs 6,364.91 crore, up 7.97% Y-o-Y

  • Aurobindo Pharma Q3 net profit zooms over 4-fold to Rs 2,946.32 crore Feb 10, 2021 10:20 PM IST

    Aurobindo Pharma Q3 net profit zooms over 4-fold to Rs 2,946.32 crore

    The company had posted a net profit of Rs 705.31 crore in the corresponding period of the previous fiscal, Aurobindo Pharma said in a filing to BSE.

  • Aurobindo Pharma Q3 PAT seen up 17.2% YoY to Rs. 719 cr: Prabhudas Lilladher Jan 18, 2021 10:47 PM IST

    Aurobindo Pharma Q3 PAT seen up 17.2% YoY to Rs. 719 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 15.5 percent Y-o-Y (up 5 percent Q-o-Q) to Rs. 5,799.4 crore, according to Prabhudas Lilladher.

  • Buy Aurobindo Pharma: target of Rs 1024: Sharekhan Dec 18, 2020 01:46 PM IST

    Buy Aurobindo Pharma: target of Rs 1024: Sharekhan

    Sharekhan is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1024 in its research report dated December 17, 2020.

  • COVID Vaccine: The opportunities for investors - Part I Dec 11, 2020 08:32 AM IST

    COVID Vaccine: The opportunities for investors - Part I

    Vaccine rollout will throw up opportunities not just for the domestic pharmaceutical and healthcare industry but also the logistics value chain, right from vaccine production, delivery, storage and then the actual immunisation

  • Aurobindo Pharma completes sale of Natrol LLC to New Mountain Capital Dec 01, 2020 12:13 PM IST

    Aurobindo Pharma completes sale of Natrol LLC to New Mountain Capital

    Earlier, Aurobindo Pharma Managing Director N Govindarajan had said that proceeds from Natrol’s divestiture will be used to reduce debt and other new strategic initiatives.

  • Accumulate Aurobindo Pharma; target of Rs 921: Prabhudas Lilladher Nov 18, 2020 01:57 PM IST

    Accumulate Aurobindo Pharma; target of Rs 921: Prabhudas Lilladher

    Prabhudas Lilladher recommended accumulate rating on Aurobindo Pharma with a target price of Rs 921 in its research report dated November 12, 2020.

  • Buy Aurobindo Pharma; target of Rs 1025: ICICI Direct Nov 17, 2020 11:22 AM IST

    Buy Aurobindo Pharma; target of Rs 1025: ICICI Direct

    ICICI Direct is bullish on Aurobindo Pharma recommended buy rating on the stock with a target price of Rs 1025 in its research report dated November 12, 2020.

  • Buy Aurobindo Pharma; target of Rs 980: Motilal Oswal Nov 15, 2020 11:56 AM IST

    Buy Aurobindo Pharma; target of Rs 980: Motilal Oswal

    Motilal Oswal is bullish on Aurobindo Pharma recommended buy rating on the stock with a target price of Rs 980 in its research report dated November 12, 2020.

  • Buy Aurobindo Pharma: target of Rs 1024: Sharekhan Nov 15, 2020 11:31 AM IST

    Buy Aurobindo Pharma: target of Rs 1024: Sharekhan

    Sharekhan is bullish on Aurobindo Pharma recommended buy rating on the stock with a target price of Rs 1024 in its research report dated November 12, 2020.

  • Aurobindo Pharma: Leaner balance sheet and cash flows are bright spots Nov 13, 2020 10:14 AM IST

    Aurobindo Pharma: Leaner balance sheet and cash flows are bright spots

    Key positives for Aurobindo Pharma are sustained performance in the anti-retroviral category and the traction in the US business

  • Aurobindo Pharma says ready to manufacture COVID-19 vaccines for others Nov 12, 2020 01:37 PM IST

    Aurobindo Pharma says ready to manufacture COVID-19 vaccines for others

    This will be in addition to its own efforts to develop a vaccine. The company said it is investing Rs 250-Rs 275 crore on a new facility to manufacture vaccines that would be ready by April. The facility will have the capacity to manufacture 400 - 450 million doses of vaccines.

  • Aurobindo Pharma shares up 4% after Q2 PAT rises 26% YoY Nov 12, 2020 09:48 AM IST

    Aurobindo Pharma shares up 4% after Q2 PAT rises 26% YoY

    Consolidated revenue from operations grew by 15.8 percent year-on-year to Rs 6,483.3 crore with the US formulation business showing a 12.5 percent growth YoY at Rs 3,189.8 crore in Q2.

  • Aurobindo Pharma Q2 profit jumps 26% to Rs 805.6 crore; US business grows 12.5% Nov 11, 2020 07:49 PM IST

    Aurobindo Pharma Q2 profit jumps 26% to Rs 805.6 crore; US business grows 12.5%

    ARV revenue at Rs 502.7 crore increased 111.4 percent YoY and API revenue at Rs 829 crore rose 2.9 percent YoY for the quarter ended September 2020, the company said in its BSE filing.

  • Buy Aurobindo Pharma; target of Rs 985: Motilal Oswal Oct 28, 2020 01:19 PM IST

    Buy Aurobindo Pharma; target of Rs 985: Motilal Oswal

    Motilal Oswal is bullish on Aurobindo Pharma recommended buy rating on the stock with a target price of Rs 985 in its research report dated October 26, 2020.

  • Buy Aurobindo Pharma; target of Rs 1025: ICICI Direct Oct 27, 2020 02:00 PM IST

    Buy Aurobindo Pharma; target of Rs 1025: ICICI Direct

    ICICI Direct is bullish on Aurobindo Pharma recommended buy rating on the stock with a target price of Rs 1025 in its research report dated October 26, 2020.

  • Natrol sale marks a subtle shift in Aurobindo Pharma’s business strategy Oct 27, 2020 09:24 AM IST

    Natrol sale marks a subtle shift in Aurobindo Pharma’s business strategy

    The Natrol sale will help Aurobindo Pharma focus on the core generic drug and injectable businesses

  • Aurobindo Pharma share price rises 4% as subsidiary sells business assets Oct 26, 2020 10:34 AM IST

    Aurobindo Pharma share price rises 4% as subsidiary sells business assets

    Jefferies served as the sole financial adviser and Sullivan & Cromwell LLP acted as legal counsel to Aurobindo.

  • Buy Aurobindo Pharma; target of Rs 1030: Motilal Oswal Sep 28, 2020 11:22 PM IST

    Buy Aurobindo Pharma; target of Rs 1030: Motilal Oswal

    Motilal Oswal is bullish on Aurobindo Pharma recommended buy rating on the stock with a target price of Rs 1030 in its research report dated September 27, 2020.

Sections